Aducanumab accepted into EMA's PRIME Program

Neurimmune's collaboration partner Biogen announced today, that Aducanumab, its investigational treatment for early Alzheimer's Disease (AD), was accepted into the European Medicines Agency's (EMA) PRiority MEdicines (PRIME) program. PRIME aims to bring treatments to patients faster by enhancing the EMA's support for the development of investigational medicines for diseases without available treatment or in need of better treatment options.